Merck and Moderna have started recruiting for a phase III trial testing their personalised cancer therapy for high risk melanoma, V940, in combination with pembrolizumab.

Read more below:
hubs.la/Q02wjLK00

☀️🌴 Mark your calendars for #ImmunoUS24 ! Join a community dedicated to advancing commercially viable immunotherapies to address unmet medical needs.

📆 October 28 - 29 2024
📍 San Diego, CA
🎫 Register Now: hubs.la/Q02vRt8r0

#OGImmuno

Your participation made #Immuno24 a resounding success. We hope you found the discussions enlightening and the connections valuable 🧬

Our next Immuno event will be #ImmunoUS24 scheduled to take place on 28th - 29th Oct. Get details here: hubs.la/Q02v8tsw0

#OGImmuno

💉 Artiva Biotherapeutics has announced, in the first clinical trial of its kind, that it has begun dosing lupus nephritis patients with their natural killer cell therapy AlloNK.

hubs.la/Q02tVyj50

🌟 #Immuno24 starts tomorrow! Explore cutting-edge immuno-oncology advancements, from cell & gene therapies to novel target identification strategies.

▶️ Event information: hubs.la/Q02tDvd00

#OGImmuno

Don't miss #Immuno24 happening THIS WEEK, where you can delve into the latest advancements in cancer immunotherapy discovery and development!

A big thank you to our sponsors for their invaluable support!

🎫 Last chance to register: hubs.la/Q02trdyf0

#OGimmuno

Only 1 week to go! Join us in London next week for #Immuno24 as we delve into the newest breakthroughs in cancer immunotherapies 🎉

▶️ Register now: hubs.la/Q02tb7JQ0

#OGimmuno #Immuno24

🚨 Last chance! Hurry and secure your spot at #Immuno24 , where you'll join 400+ industry leaders to explore the latest breakthroughs in cancer immunotherapy.

▶️ Register here: hubs.la/Q02sp6ms0

➡️ Explore details: hubs.la/Q02sp6ms0

#OGImmuno

A paper published in Nature Communications has outlined the results from a phase I/II clinical trial investigating invariant natural killer T (iNKT) cell therapy for moderate-severe acute respiratory distress syndrome (ARDS).

Read more here: hubs.ly/Q02snqQs0

🚨 HAPPENING TODAY! 🚨

Last chance to register and hear Katrina Bykova and Volker Huppert explore methods to enhance immune response and target NK cells effectively.

🕓 16:00 BST | 08:00 PDT
🖥️ Register here: hubs.la/Q02rtZxg0

#OGImmuno #NKCells

⚠️ 𝐀𝐂𝐓 𝐍𝐎𝐖! 𝐋𝐈𝐌𝐈𝐓𝐄𝐃 𝐏𝐋𝐀𝐂𝐄𝐒 𝐑𝐄𝐌𝐀𝐈𝐍𝐈𝐍𝐆! ⚠️

Secure your place now and gain profound knowledge in the rapidly evolving field of immunotherapy.

📆 Monday 8th April 2024
🕓 16:00 BST | 08:00 PDT
🖥️ Register here: hubs.la/Q02rv5Zq0

#OGImmuno #NKCells

🧬 Join our FREE webinar on NK cell engagers! Explore:

✔️ Overcoming immune activity in current in vivo models
✔️ Expanding & engaging NK cell populations
✔️ Feasibility of targeting NK cells with low persistence

🖥️ Register: hubs.la/Q02qq2sc0

#OGImmuno

Don't miss our FREE webinar where Katrina Bykova and Volker Huppert will discuss harnessing the immune system with NK cell engagers! 🧬

📆 Monday 8th April 2024
🕓 16:00 BST | 08:00 PDT
🖥️ Register here: hubs.la/Q02pYGRs0

#OGImmuno #NKCell

More results are in for the oncolytic potential of the Zika virus, where it has proven effective against the most common form of brain cancer in vitro.

hubs.la/Q02p_4230

📢[𝗔𝗡𝗡𝗢𝗨𝗡𝗖𝗘𝗠𝗘𝗡𝗧] Media Partnership with SelectScience

Collaborating across all 7 OG brands, #SelectScience are accelerating science by connecting scientific communities with trusted solutions: hubs.la/Q02pN89v0

#OGMediaPartner

Join our free monthly science exchange webinar featuring Katrina Bykova and Volker Huppert as they dive into the fascinating world of harnessing the immune system with NK cell engagers! 🖥️

▶️ Register here: hubs.la/Q02pfFs-0

#OGImmuno #NKCell

Discover cutting-edge oncology and immuno-oncology solutions with Crown Bioscience at Immuno 2024 and explore their top-tier preclinical models 🔬

Discover more: hubs.la/Q02mRgSF0

#OGImmuno

Unlock the full potential of biopharmaceutical development with Batavia Biosciences at #Immuno24 . From cloning to GMP manufacture & clinical material release for phase I/II studies, their personalised services cover every stage 🤝

➡️ Agenda: hubs.la/Q02mx-tB0

#OGImmuno

One of the deadliest cancers in children could have its survival rate improved by the advent of new research into the oncolytic effect of Zika virus.

Read more: hubs.la/Q02np2Wc0

Learn about @Lunaphore's ground-breaking chip technology at #Immuno24 ! Explore how their innovation extracts spatial proteomic and genomic data from tumours, simplifying assays into multiplex spatial biology 🧬

➡️ View agenda: hubs.la/Q02mxtg50

#OGImmuno